Cervical & ovarian cancer specialist Dr John Chia

Dr Lynette Ngo

Medical Oncologist

MBBS (S’pore), M Med (Int Med), MRCP (UK), Dip Palliative Med (Aus), FAMS (Medical Oncology)

Biography

Dr Lynette Ngo is a medical oncologist who specializes in women’s cancers – breast and gynaecologic cancers including ovary, endometrial, uterine and cervical cancers.

Dr Ngo graduated from National University of Singapore in 1996. She further pursued a Master of Medicine degree in Internal Medicine and obtained her membership of the Royal College of Physicians in UK in 2002. She received her post graduate Diploma in Palliative Medicine from Edith Cowan University in Australia in 2006 and obtained her specialist accreditation in medical oncology from the Academy of Medicine, Singapore in 2007. She is a member of the American Society of Clinical Oncology (ASCO), European Society of Clinical Oncology (ESMO), Asian Society of Gynaecologic Oncology (ASGO) and Singapore Society of Oncology (SSO). She serves on the Singapore Cancer Network (SCAN) guidelines committee.

Prior to Curie Oncology, Dr Ngo had been practising at National Cancer Centre, Singapore (NCCS) from 2005 to 2012 before moving to Raffles Cancer Centre, Raffles Hospital from 2012 to 2019. Aside from being a Clinical Tutor at the Yong Loo Lin Medical School, she was also a Visiting Consultant to both KKWCH Gynaecologic Cancer Centre and KKWCH Breast Centre as well as to Khoo Teck Puat Hospital. In addition, she spent 5 years caring for patients in hospice home care and in-patient hospice services in the community prior to joining NCCS.

Dr Ngo’s areas of interest are in breast and gynaecologic cancers, hereditary cancers and genetic counselling, psychosocial oncology and palliative medicine, in addition to general medical oncology. In pursuing her sub-specialty interest in gynaecologic cancers, Dr Ngo was awarded the Health Manpower Development Programme Award to spend a year at the Gillette Center for Gynecologic Oncology at Massachusetts General Hospital (MGH), USA. In collaboration with the MGH gynaecologic oncology team, she designed and conducted several investigator-initiated clinical trials, testing novel drugs and treatment strategies in subsets of gynaecologic cancers with molecularly defined pathways. She had received a grant from the Singhealth Foundation for her research work and was involved in multiple clinical trials in Raffles Hospital focusing on breast and gynaecologic cancers. She has contributed to numerous publications in peer reviewed journals and written book chapters.

Recognizing the challenges faced by patients, caregivers, and even survivors, Dr Ngo started the Raffles Cancer Support Programme in April 2013 to provide education, psychosocial and emotional support throughout the cancer journey.

Dr Ngo has also completed the Intensive Course in Cancer Risk Assessment at City of Hope Hospital in California, USA from Oct 2017 to Mar 2018. She established the Hereditary Cancer Risk assessment clinic and genetic counselling in Raffles Hospital.

Area of Interest

Breast cancer

Gynaecological cancers

Curie Oncology Locations

Mount Elizabeth Novena Specialist Centre

Farrer Park Medical Centre

Publications

Media

Clinical Trials

-

Clinical Trials

No.Tumor TypeStageStudy TitlePrincipal InvestigatorDetailsStatus
1Lung CancerIVA Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung CancerDr Toh Chee Keong#NCT04262856Open
2Breast cancerIVA Randomized, multicentre, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of ER(+), HER(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced diseaseDr Lynette Ngo#NCT04478266Open
3Hepatocellular carcinomaIVA Phase III, Randomized Double-blind, Placebo-controlled, Multicentre Study of Transarterial Chemoembolization (TACE) in Combination With either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)Dr Choo Su Pin#NCT03778957

Emerald-1 Trial Patient Information
Open
4Endometrial cancer IVA Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer(DUO-E)Dr Lynette Ngo#NCT04269200Open
5Gastric cancerIVA Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) Combined with Chemotherapy versus Placebo Combined with Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerDr Choo Su Pin#NCT04139135Closed

Open chat
Need help?
Hello! Welcome to Curie Oncology!
How can we help you?